Description
Spevigo (spesolimab-sbzo) is a prescription medication that is used to treat adult patients with moderate to severe plaque psoriasis. It is administered as a subcutaneous injection and works by blocking a specific protein that causes inflammation in the body.
Uses:
Spevigo is indicated for the treatment of adult patients with moderate to severe plaque psoriasis. Plaque psoriasis is a chronic autoimmune disease that causes thick, scaly patches on the skin that can be itchy and painful.
Storage conditions:
Spevigo should be stored in a refrigerator at a temperature between 2°C to 8°C (36°F to 46°F). It should not be frozen or exposed to light. The medication should be kept in its original packaging and out of reach of children.
Mechanism of action:
Spevigo works by blocking a protein called interleukin-31 (IL-31), which is involved in the immune system’s response that causes psoriasis symptoms such as inflammation, redness, scaling, and itching on the skin.
HOW TO USE:
Spevigo is given as a subcutaneous injection under the skin by a healthcare provider. The recommended dose is 300 mg every four weeks for the first three doses, followed by 450 mg every 12 weeks. The injection should be given in a different site each time and the patient should be monitored for reactions after the injection.
Precautions:
Patients should inform their healthcare provider if they have a history of hypersensitivity reactions to Spevigo or any of its components. The medication may increase the risk of infections, so patients should be monitored for signs of infections and should avoid contact with individuals with active infections. Patients should also avoid live vaccines while taking this medication.
Drug interactions:
The use of Spevigo with other medications has not been studied extensively, and interactions with other drugs are not yet known. Patients should inform their healthcare providers of all medications, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins that they are taking.
Contraindications:
Spevigo is contraindicated in patients with a known hypersensitivity to spesolimab-sbzo or any of the components in the medication. It should not be used in patients with a known active infection or history of recurrent infections. Patients with weakened immune systems should also not receive this medication.
Overdose:
There is limited information available on the effects of an overdose of Spevigo. If an overdose is suspected, the patient should seek immediate medical attention.
Adverse reactions:
The most common side effects associated with Spevigo include upper respiratory tract infections, injection site reactions, diarrhea, headache, and fungal skin infections. Serious side effects are rare but may occur. Patients should be monitored for adverse reactions during and after each injection.
In summary, Spevigo is a subcutaneous injection medication used to treat moderate to severe plaque psoriasis by blocking interleukin-31. It is given every four weeks for the first three doses, followed by every 12 weeks, always in different injection sites. Patients should be monitored for infections, hypersensitivity reactions, and drug interactions. Upper respiratory tract infections, injection site reactions, and headache are common side effects of this medication.
Reviews
There are no reviews yet.